Identification and Validation of RELN Mutation as a Response Indicator for Immune Checkpoint Inhibitor Therapy in Melanoma and Non-Small Cell Lung Cancer

Remarkable clinical benefits in several advanced cancers are observed under the treatment of immune checkpoint inhibitor (ICI) agents. However, only a smaller proportion of patients respond to the treatments. Reelin (RELN) is frequently mutated in the cancer genome. In this study, the RELN mutation...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zhenpeng, Wang, Xin, Yang, Yi, Shi, Fuyan, Zhang, Wenjing, Wang, Qinghua, Wang, Suzhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741468/
https://www.ncbi.nlm.nih.gov/pubmed/36497098
http://dx.doi.org/10.3390/cells11233841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741468/
https://www.ncbi.nlm.nih.gov/pubmed/36497098
http://dx.doi.org/10.3390/cells11233841

Ejemplares similares